Perceptions of genetic testing and genomic medicine among drug users

David C. Perlman, Camila Gelpí-Acosta, Samuel R. Friedman, Ashly E. Jordan, Holly Hagan

Research output: Contribution to journalArticle

Abstract

Background: Genetic testing will soon enter care for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and for addiction. There is a paucity of data on how to disseminate genetic testing into healthcare for marginalized populations. We explored drug users' perceptions of genetic testing. Methods: Six focus groups were conducted with 34 drug users recruited from syringe exchange programmes and an HIV clinic between May and June 2012. Individual interviews were conducted with participants reporting previous genetic testing. Results: All participants expressed acceptance of genetic testing to improve care, but most had concerns regarding confidentiality and implications for law enforcement. Most expressed more comfort with genetic testing based on individual considerations rather than testing based on race/ethnicity. Participants expressed comfort with genetic testing in medical care rather than drug treatment settings and when specifically asked permission, with peer support, and given a clear rationale. Conclusion: Although participants understood the potential value of genetic testing, concerns regarding breaches in confidentiality and discrimination may reduce testing willingness. Safeguards against these risks, peer support, and testing in medical settings based on individual factors and with clear rationales provided may be critical in efforts to promote acceptance of genetic testing among drug users.

Original languageEnglish (US)
Pages (from-to)100-106
Number of pages7
JournalInternational Journal of Drug Policy
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Genetic Testing
Drug Users
Medicine
Confidentiality
Needle-Exchange Programs
HIV
Law Enforcement
Focus Groups
Hepacivirus
Interviews
Delivery of Health Care

Keywords

  • Drug users
  • Genetic testing
  • HCV
  • HIV
  • Perceptions
  • Racial/ethnic minorities

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Policy

Cite this

Perceptions of genetic testing and genomic medicine among drug users. / Perlman, David C.; Gelpí-Acosta, Camila; Friedman, Samuel R.; Jordan, Ashly E.; Hagan, Holly.

In: International Journal of Drug Policy, Vol. 26, No. 1, 01.01.2015, p. 100-106.

Research output: Contribution to journalArticle

Perlman, David C. ; Gelpí-Acosta, Camila ; Friedman, Samuel R. ; Jordan, Ashly E. ; Hagan, Holly. / Perceptions of genetic testing and genomic medicine among drug users. In: International Journal of Drug Policy. 2015 ; Vol. 26, No. 1. pp. 100-106.
@article{5ee9c1d24d19430894e2bcdad9b140b7,
title = "Perceptions of genetic testing and genomic medicine among drug users",
abstract = "Background: Genetic testing will soon enter care for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and for addiction. There is a paucity of data on how to disseminate genetic testing into healthcare for marginalized populations. We explored drug users' perceptions of genetic testing. Methods: Six focus groups were conducted with 34 drug users recruited from syringe exchange programmes and an HIV clinic between May and June 2012. Individual interviews were conducted with participants reporting previous genetic testing. Results: All participants expressed acceptance of genetic testing to improve care, but most had concerns regarding confidentiality and implications for law enforcement. Most expressed more comfort with genetic testing based on individual considerations rather than testing based on race/ethnicity. Participants expressed comfort with genetic testing in medical care rather than drug treatment settings and when specifically asked permission, with peer support, and given a clear rationale. Conclusion: Although participants understood the potential value of genetic testing, concerns regarding breaches in confidentiality and discrimination may reduce testing willingness. Safeguards against these risks, peer support, and testing in medical settings based on individual factors and with clear rationales provided may be critical in efforts to promote acceptance of genetic testing among drug users.",
keywords = "Drug users, Genetic testing, HCV, HIV, Perceptions, Racial/ethnic minorities",
author = "Perlman, {David C.} and Camila Gelp{\'i}-Acosta and Friedman, {Samuel R.} and Jordan, {Ashly E.} and Holly Hagan",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.drugpo.2014.06.013",
language = "English (US)",
volume = "26",
pages = "100--106",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Perceptions of genetic testing and genomic medicine among drug users

AU - Perlman, David C.

AU - Gelpí-Acosta, Camila

AU - Friedman, Samuel R.

AU - Jordan, Ashly E.

AU - Hagan, Holly

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Genetic testing will soon enter care for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and for addiction. There is a paucity of data on how to disseminate genetic testing into healthcare for marginalized populations. We explored drug users' perceptions of genetic testing. Methods: Six focus groups were conducted with 34 drug users recruited from syringe exchange programmes and an HIV clinic between May and June 2012. Individual interviews were conducted with participants reporting previous genetic testing. Results: All participants expressed acceptance of genetic testing to improve care, but most had concerns regarding confidentiality and implications for law enforcement. Most expressed more comfort with genetic testing based on individual considerations rather than testing based on race/ethnicity. Participants expressed comfort with genetic testing in medical care rather than drug treatment settings and when specifically asked permission, with peer support, and given a clear rationale. Conclusion: Although participants understood the potential value of genetic testing, concerns regarding breaches in confidentiality and discrimination may reduce testing willingness. Safeguards against these risks, peer support, and testing in medical settings based on individual factors and with clear rationales provided may be critical in efforts to promote acceptance of genetic testing among drug users.

AB - Background: Genetic testing will soon enter care for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and for addiction. There is a paucity of data on how to disseminate genetic testing into healthcare for marginalized populations. We explored drug users' perceptions of genetic testing. Methods: Six focus groups were conducted with 34 drug users recruited from syringe exchange programmes and an HIV clinic between May and June 2012. Individual interviews were conducted with participants reporting previous genetic testing. Results: All participants expressed acceptance of genetic testing to improve care, but most had concerns regarding confidentiality and implications for law enforcement. Most expressed more comfort with genetic testing based on individual considerations rather than testing based on race/ethnicity. Participants expressed comfort with genetic testing in medical care rather than drug treatment settings and when specifically asked permission, with peer support, and given a clear rationale. Conclusion: Although participants understood the potential value of genetic testing, concerns regarding breaches in confidentiality and discrimination may reduce testing willingness. Safeguards against these risks, peer support, and testing in medical settings based on individual factors and with clear rationales provided may be critical in efforts to promote acceptance of genetic testing among drug users.

KW - Drug users

KW - Genetic testing

KW - HCV

KW - HIV

KW - Perceptions

KW - Racial/ethnic minorities

UR - http://www.scopus.com/inward/record.url?scp=84919845939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919845939&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2014.06.013

DO - 10.1016/j.drugpo.2014.06.013

M3 - Article

C2 - 25037119

AN - SCOPUS:84919845939

VL - 26

SP - 100

EP - 106

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

IS - 1

ER -